A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia | Zendy

Cherng-Ru Hsu | Zendy; YiHsun Chen | Zendy; Chih-Peng Liu | Zendy; ChihHung Chen | Zendy; KuoKuei Huang | Zendy; JuiWen Huang | Zendy; Meng-Nan Lin | Zendy; ChihLung Lin | Zendy; Wanru Chen | Zendy; YiLing Hsu | Zendy; Tze-Chung Lee | Zendy; Shuen-Hsiang Chou | Zendy; Chia-Mu Tu | Zendy; Chrong-Shiong Hwang | Zendy; Yu Chuan Huang | Zendy; DaWen Lu | Zendy

Open Access

A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia

Author(s) -

Cherng-Ru Hsu,

YiHsun Chen,

Chih-Peng Liu,

ChihHung Chen,

KuoKuei Huang,

JuiWen Huang,

Meng-Nan Lin,

ChihLung Lin,

Wanru Chen,

YiLing Hsu,

Tze-Chung Lee,

Shuen-Hsiang Chou,

Chia-Mu Tu,

Chrong-Shiong Hwang,

Yu Chuan Huang,

DaWen Lu

Publication year - 2019

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-25252

Subject(s) - pharmacology , tolerability , pharmacokinetics , medicine , chemistry , in vivo , kinase , adverse effect , biochemistry , biology , microbiology and biotechnology

The purpose of this study was to investigate the IOP-lowering effects of the ITRI-E-212, a new Rho-associated protein kinase (ROCK) inhibitor. ITRI-E-212 improved fluid outflow through the trabecular meshwork and reduced IOP with transient and mild conjunctival hyperemia. ITRI-E-212 can potentially be developed into new antiglaucoma agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research